Hubungan antara Ekspresi Ki-67 dan Kaspase-3 dengan Respons Kemoterapi Neoajuvan pada Pasien Karsinoma Serviks Stadium IB2 dan IIA2 di Rumah Sakit Dr. Hasan Sadikin, Bandung

I MADE WIDYALAKSANA MAHAYASA, MARINGAN DIAPARI LUMBAN TOBING, ALI BUDI HARSONO

Abstract


ABSTRACT
Cervical carcinoma is the second ranks cancer in women in developing countries. This study was a retrospective cohort
study of the relationship between the role of Ki-67 expression and caspase-3 on tumor shrinkage response in cervical carcinoma stage IB2 and IIA2. A total of 41 cases have been done NACT with Cisplatin, Vincristine and Bleomycin. All samples showed expression in immunohistochemical staining for Ki-67 and caspase-3. Meanwhile, Pearson correlation analysis found no correlation between the expression levels of Ki-67 and caspase-3 with a diminution of
tumor mass (p>0.05). While the correlation between the ratio of Ki-67 expression and caspase-3 with a significant diminution of tumor mass is obtained p 0.042, R-0.319, means that the higher the Ki-67 expression levels compared caspase-3 expression level then the response of the tumor mass size reduction will be better.


ABSTRAK
Karsinoma serviks merupakan kanker kedua terbanyak pada wanita di negara berkembang. Penelitian ini merupakan penelitian kohort retrospektif yang mempelajari hubungan antara peran ekspresi Ki-67 dan kaspase-3 terhadap respons pengecilan tumor pada karsinoma serviks stadium IB2 dan IIA2. Sebanyak 41 kasus telah dilakukan KTNA dengan Cisplatin, Vincristin, dan Bleomycin (PVB).
Hasil penelitian menunjukkan seluruh sampel ekspresi pada pewarnaan imunohistokimia untuk Ki-67 dan kaspase-3. Sedangkan analisis korelasi Pearson tidak didapatkan korelasi antara tingkat ekspresi ki-67 dan kaspase-3 dengan pengecilan massa tumor dan nilai p>0,05. Sedangkan korelasi antara rasio ekspresi Ki-67 dan kaspase-3 dengan pengecilan massa tumor didapatkan bermakna dengan nilai p = 0,042 (p<0,05), R-0,319. Artinya, semakin tinggi proliferasi (tingkat ekspresi Ki-67) dibandingkan dengan apoptosis (tingkat ekspresi kaspase-3) maka respons pengecilan tumor akan semakin baik pada karsinoma serviks stadium IB2 dan IIA2


Keywords


Cervical carcinoma bulky, response, chemotherapy neoajuvan, Ki-67, caspase-3, ratio, reduction of tumor

References


WHO, WHO/ICO Information Centre on HPV and Cervical Cancer

(HPV Information Centre). Barcelona, 2014.

Laporan Tahunan Bagian Obstetri dan Ginekologi RSHS: Bagian

Obstetri dan Ginekologi. 2014.

Tobing MDL, Peran P-170 Glycoprotein, Metilasi DNA Gen MDR 1

dan Antibodi Anti-CD34 pada Respons Kemoterapi Neoajuvan

(KTNA) pada Karsinoma serviks Stadium IB2 dan IIA2, (Disertasi),

Universitas Padjadjaran, Bandung, 2014.

Andrijono, Karsinoma serviks. Edisi IV. Jakarta. Balai Penerbit

Fakultas Kedokteran Universitas Indonesia, 2012.

Berek JS, Hacker NF. Practical Gynecologic Oncology. Edisi kelima.

Philadelphia: Lippincott Williams & Wilkins, 2010.

Saha A, Mukherjee A. Role of Neoadjuvant Chemotherapy in Cancer

Cervix: A Brief Review. Clin Cancer Investig J, October-December

;2, Issue 4. Balacescu O, Balacescu L, Tudoran O dkk. Gene

Expression Profiling Reveals Activation of the FA/BRCA Pathway

Advanced Squamous Cervical Cancer with Intrinsic Resistance and

Therapy Failure. Biomed Central Cancer 2014;14:246.

Vandecasteele K, Makar A, Van den Broecke R dkk. Intensity

Modulated Arc Therapy with Cisplatin as Neoadjuvant Treatment for

Primary Irresectabel Cervical Cancer. Toxicity, Tumour Response and

Outcome. Strahlenther Onkol. 2012; 188:576–81.

Katsumata N, Yoshikawa H, Kobayashi H dkk. Phase III Randomized

Controlled Trial of Neoadjuvant Chemotherapy Plus Radical Surgery

vs Radical Surgery Alone for Stages IB2, IIA2, and IIB Cervical

Cancer: Japan Clinical Oncology Group trial (JCOG 0102). Br Cancer

;108:157-63.

Mattern J, Volm M, Imbalance of Cell Proliferation and Apoptosis

During Progression of Lung Carcinomas. Anticancer Res.

;24:4243-6.

Cundiff C, Karthikeyan M, Kumar G. S dkk. Gene Expression Analysis

of Cervical Cancer Progression, Genomics and Bioinformatics,

Georgia Tech, 2013.

Bascones-Martínez A, Rodríguez-Gutierrez C, Rodríguez-Gómez

E dkk. Evaluation of p53, Kaspase-3, Bcl-2, and Ki-67 markers in oral

squamous cell carcinoma and premalignant epithelium in a sample

from Alava Province (Spain). Med Oral Patol Oral Cir Bucal 2013;18:

e846-50.

Gandamihardja S,Wirakusumah FF, Shahib N dkk. Peran

Siklooksigenase dalam Pertumbuhan Kanker Leher Rahim, MKB, vol

, Tahun 2010.

Ross W, Hall PA, Ki-67: From Antibody to Molecule to

Understanding? J. Clin Pathol 1995;48:M113-M117.

Vasilescu F, Ceausu M, Tanase C dkk. P53, p63 and Ki-67 Assessment

in HPV-induced Cervical Neoplasia. Rom J Morphol Embryol.

;50:357–61.

Marjorie CH, Pacioles-Flavier, Luna Jericho TP, The Correlation of

Ki-67 Expression with Tumor Recurrence and Survival

Rates in Early Stage Carcinoma of the Cervix. Phil J Obstet Gynecol.

;33:1-37.

Okuno Y, Nishimura Y, Kashu I dkk. Prognostic Values of Proliferating

Cell Nuclear Antigen (PCNA) and Ki-67 for Radiotherapy of

Oesophageal Squamous Cell Carcinomas. Br J Cancer

;80:387–95.

Nam EJ, Kim JW, Hong JW dkk. Expression of the p16 INK4a

and Ki-67 in Relation to the Grade of Cervical Intraepithelial

Neoplasia and High-Risk Human Papillomavirus Infection. Japan

Gynecol Oncol. 2008;19:162-8.

Ancuta E, Ancuta C, Lauretta GC dkk. Tumor Biomarkers in Cervical

Cancer: Focus on Ki-67 Proliferation Factor and E-Cadherin

Expression. Rom J Morphol Embryol 2009;50:413–8.

Kobayashi K, Furukawa A, Takahashi M dkk. Neoadjuvant Intra-

Arterial Chemotherapy for Locally Advanced Uterine Cervical Cancer:

Clinical Efficacy and Factors Influencing Response, Springer-Verlag

New York, Inc. Cardiovasc Intervent Radiol 2003;26:234–41.


Full Text: PDF

DOI: 10.14414/ijoc.v10i2.425

Article Metrics

Abstract view : 326 times
PDF - 225 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Indonesian Journal of Cancer